Head to Head Analysis: Scienture (NASDAQ:SCNX) versus Universe Pharmaceuticals (NASDAQ:UPC)

Scienture (NASDAQ:SCNX) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Profitability

This table compares Scienture and Universe Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scienture	N/A	-53.51%	-42.47%
Universe Pharmaceuticals	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Scienture and Universe Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scienture	1	0	1	0	2.00
Universe Pharmaceuticals	1	0	0	0	1.00

Scienture currently has a consensus price target of $1.50, suggesting a potential upside of 232.59%. Given Scienture’s stronger consensus rating and higher possible upside, research analysts plainly believe Scienture is more favorable than Universe Pharmaceuticals.

Volatility & Risk

Scienture has a beta of 3.26, meaning that its stock price is 226% more volatile than the S&P 500. Comparatively, Universe Pharmaceuticals has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500.

Institutional and Insider Ownership

5.7% of Scienture shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 21.4% of Scienture shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Scienture and Universe Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scienture	$430,000.00	42.61	-$41.51 million	($2.10)	-0.21
Universe Pharmaceuticals	$17.86 million	1.59	-$3.67 million	N/A	N/A

Universe Pharmaceuticals has higher revenue and earnings than Scienture.

Summary

Scienture beats Universe Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.

About Universe Pharmaceuticals

Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji’An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.